Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of Safety, Tolerability and Immunological Effects of SVN53-67/M57-KLH in Patients With Survivin-Positive Malignant Gliomas

NCT01250470 is registered in ClinicalTrials.gov with Roswell Park Cancer Institute as lead sponsor.

NCT NCT01250470
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01250470 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of Safety, Tolerability and Immunological Effects of SVN53-67/M57-KLH in Patients With Survivin-Positive Malignant Gliomas
Lead sponsor
Roswell Park Cancer Institute
Phase
Phase 1
Overall status
Completed
Start date
September 5, 2012
Completion date
May 29, 2014
Enrollment
9 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anaplastic astrocytoma, anaplastic oligoastrocytoma, anaplastic oligodendroglioma, giant cell glioblastoma, glioblastoma, gliosarcoma, mixed glioma, recurrent brain neoplasm